Default Category
-
Moleskine (A)
Raffaelli, Ryan L.; Sadun, Raffaella; Qu, KathyCase HBS-716407-ELeadership and People ManagementDescribes the founding and growth challenges facing Moleskine, an Italian-based consumer products company known for its oilcloth-covered notebooks once used by Ernest Hemingway and Vincent van Gogh. CEO Arrigo Berni and co-founder Maria Sebregondi aim to transform the company from a founder-led company to a professionally managed firm by expanding into new geographies, product categories, and distribution channels. They have also recently develop...Starting at €8.20
-
Henry Schein: Doing Well by Doing Good
Henderson, Rebecca M.; Sesia, Aldo; Eisenstat, Russell A.; Sadun, RaffaellaCase HBS-714450-EStrategyHenry Schein Inc., a distributor of supplies to dentist, physician, and veterinary practices, had sales approaching $9 billion and employed nearly 16,000 people. The company had experienced impressive growth under the leadership of Stanley Bergman and his executive team, many of whom had been with Schein for decades. Besides organic growth, the company relied heavily on acquiring small family-owned businesses to grow, both inside the U.S., and ab...Starting at €8.20
-
Henry Schein: Doing Well by Doing Good, Teaching Note
Sadun, RaffaellaTeaching Note HBS-714492-EStrategyTeaching Note for 714450.Starting at €0.00
-
A Managerial Perspective on Clinical Trials
Daemmrich, Arthur A.Case HBS-709033-EEntrepreneurshipThis note describes the history and regulation of clinical trials, managerial challenges related to pharmaceutical product testing, and current debates regarding prescription drug safety. Since clinical testing takes between five and seven years, and consumes up to 70 percent of a drug's total development costs, pharmaceutical and biotechnology leaders need to understand clinical trial management. Likewise, with a growing variety of new product i...Starting at €8.20
-
Arcadia Biosciences: Seeds of Change (Abridged)
Daemmrich, Arthur A.Case HBS-711050-EArcadia Biosciences is seeking to introduce genetically modified rice to China that will lower farmers' costs and generate environmental benefits through reduced greenhouse gas emissions. The case describes challenges facing this small agricultural biotechnology company, notably uneven enforcement of intellectual property in emerging market countries, and uncertainty regarding the provision and market value of carbon credits under international c...Starting at €8.20
-
Arcadia Biosciences: Seeds of Change
Daemmrich, Arthur A.; Reinhardt, Forest L.; Shelman, MaryCase HBS-709019-EArcadia Biosciences is an entrepreneurial California agricultural biotech company seeking to earn carbon credits by modifying commodity crops for use in China and India. Eric Rey, Arcadia's CEO, faced a strategic inflection point in early September, 2008. The company had a plan to share carbon credits allocated by the United Nations Clean Development Mechanism Executive Board to China, for use of Arcadia's rice varieties, since they enabled farme...Starting at €8.20
-
Arcadia Biosciences: Seeds of Change, Teaching Note
Daemmrich, Arthur A.; Reinhardt, Forest L.Teaching Note HBS-711042-ETeaching Note for 709019.Starting at €0.00
-
CyberArk: Protecting the Keys to the IT Kingdom
Sadun, Raffaella; Yoffie, David B.; Eiran, MargotCase HBS-718418-EStrategyCyberArk was the recognized leader in the Privileged Account Management (PAM) space, a cybersecurity subsegment it had essentially created to secure organizations' IT systems and sensitive data. Over 17 years, the Israeli company had grown to a market capitalization of over $1.6 billion, with sales exceeding $217 million and 900 global employees with a strong corporate culture. In May 2017, Udi Mokady, founder, chairman, and CEO, debated how best...Starting at €8.20
-
CyberArk: Protecting the Keys to the IT Kingdom, Teaching Note
Sadun, Raffaella; Friar, GretaTeaching Note HBS-718490-EStrategyTeaching note for case 718418.Starting at €0.00